Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$88.86 USD
-0.25 (-0.28%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $88.87 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Axsome Therapeutics, Inc. [AXSM]
Reports for Purchase
Showing records 1 - 20 ( 186 total )
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solriamfetol Patent Litigation Settlement Reached; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continued Sales Momentum; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solriamfetol ENGAGE Phase 3 Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-12 SYMPHONY Phase 3 Trial Yields Positive Data; Raising PT to $190
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solriamfetol PARADIGM Phase 3 Trial Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R